Opus Genetics (IRD)
4.67
+0.07 (1.52%)
Upcoming Events
Latest Headlines
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens: Focus on Viatris
August 28, 2026 4:42 AM - StreetInsider
Longeveron names Nirav Jhaveri as CFO
August 19, 2026 4:05 PM - StreetInsider
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
August 19, 2026 4:05 PM - Globe NewsWire
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2026 4:01 PM - Globe NewsWire
TD Cowen on Opus Genetics (IRD): 'High Conviction For Meaningful Efficacy'
August 19, 2026 9:14 AM - StreetInsider
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens Ahead of Phase 1/2 BIRD-1 Trial
August 19, 2026 4:31 AM - StreetInsider
Form EFFECT Opus Genetics, Inc.
August 17, 2026 6:18 AM - SEC Filing
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: PERCEPTIVE ADVISORS LLC
August 14, 2026 5:23 PM - SEC Filing
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: Caligan Partners LP
August 14, 2026 4:40 PM - SEC Filing
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
August 14, 2026 6:14 AM - SEC Filing
Opus Genetics (IRD) PT Lowered to $9 at RBC Capital
August 7, 2026 7:30 AM - StreetInsider
Form S-3 Opus Genetics, Inc.
August 7, 2026 6:22 AM - SEC Filing
Form 10-Q Opus Genetics, Inc. For: Jun 30
August 6, 2026 4:37 PM - SEC Filing
Opus Genetics, Inc. (IRD) Tops Q2 EPS by 2c
August 6, 2026 7:37 AM - StreetInsider
Form 8-K Opus Genetics, Inc. For: Aug 06
August 6, 2026 7:05 AM - SEC Filing
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
August 6, 2026 7:01 AM - Globe NewsWire
Opus Genetics completes enrollment in phase 3 eye gene therapy trial
August 3, 2026 7:00 AM - StreetInsider
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
August 3, 2026 7:00 AM - Globe NewsWire
TD Cowen Starts Opus Genetics (IRD) at Buy
July 29, 2026 5:29 AM - StreetInsider
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: YERXA BENJAMIN R
July 27, 2026 4:08 PM - SEC Filing
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: SCHACHLE JOSEPH K
July 27, 2026 4:08 PM - SEC Filing
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: Magrath George
July 27, 2026 4:07 PM - SEC Filing
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: Gagnon Robert E.
July 27, 2026 4:07 PM - SEC Filing
Form 144 Opus Genetics, Inc. Filed by: Gagnon Robert E.
July 23, 2026 5:22 PM - SEC Filing
Form 144 Opus Genetics, Inc. Filed by: Magrath George
July 23, 2026 5:18 PM - SEC Filing
Form 144 Opus Genetics, Inc. Filed by: SCHACHLE JOSEPH K
July 23, 2026 1:09 PM - SEC Filing
Form 144 Opus Genetics, Inc. Filed by: YERXA BENJAMIN R
July 23, 2026 12:47 PM - SEC Filing
Opus Genetics (IRD) Reiterated at Overweight by Cantor Fitzgerald on Positive Update
July 10, 2026 6:45 AM - StreetInsider
Opus Genetics sets September timeline for OPGx-BEST1 trial data
July 9, 2026 7:02 AM - StreetInsider
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
July 9, 2026 7:00 AM - Globe NewsWire
BTIG on Opus Genetics (IRD): 'the path from here to BLA submission seems clear'
July 6, 2026 12:06 PM - StreetInsider
B.Riley on Opus Genetics (IRD): 'we remain buyers'
July 6, 2026 12:05 PM - StreetInsider
Opus Genetics gets FDA alignment on Phase 3 eye gene therapy trial
July 6, 2026 7:01 AM - StreetInsider
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
July 6, 2026 7:00 AM - Globe NewsWire
Opus Genetics added to Russell 3000, 2000, and Microcap indexes
June 26, 2026 9:15 AM - StreetInsider
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
June 26, 2026 9:15 AM - Globe NewsWire
RBC Capital Starts Opus Genetics (IRD) at Outperform
June 23, 2026 6:40 AM - StreetInsider
Form 424B2 Opus Genetics, Inc.
June 17, 2026 7:26 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)
June 17, 2026 6:49 AM - StreetInsider
Form EFFECT Opus Genetics, Inc.
June 17, 2026 6:03 AM - SEC Filing
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens after R&D Day
June 17, 2026 4:19 AM - StreetInsider
Form 8-K Opus Genetics, Inc. For: Jun 16
June 16, 2026 4:12 PM - SEC Filing
Opus Genetics outlines five gene therapy programs for retinal diseases
June 16, 2026 4:06 PM - StreetInsider
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
June 16, 2026 4:05 PM - Globe NewsWire
Form 8-K Opus Genetics, Inc. For: Jun 16
June 16, 2026 12:06 PM - SEC Filing
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens After Investor Meet
June 15, 2026 5:11 AM - StreetInsider
Full Article List
